Demystifying Myriad Genetics: Insights From 6 Analyst Reviews

In the preceding three months, 6 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $19.5, a high estimate of $24.00, and a low estimate of $13.00. This current average represents a 23.23% decrease from the previous average price target of $25.40.

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Myriad Genetics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Myriad Genetics compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Myriad Genetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Myriad Genetics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Myriad Genetics: A Closer Look

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics: A Financial Overview

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Positive Revenue Trend: Examining Myriad Genetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -10.36%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.0%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.04%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.